Drag a card by its title · ⚙ to size, swap or remove

The company

Bioventus Inc.

BVS · Nasdaq

Health CareMedical DevicesLeading

BVS stood above a rising 150-day average in 44 of the last 52 weekly readings, including each of the last 18 weeks. It is 24.4% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation: Leading
Weeks in an uptrend: 18 in a row
Industry in uptrend: 29% -4 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $418K
Officials’ trades on record: 0
Institutions holding: 147 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.

22 Apr – 21 Oct

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months3

Buyers · sellers0 · 2

Who	Did	Shares	Traded
Michelle McMurry-HeathDirector	sold	12,000at $8.79	11 Mar 2026filed 13 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders147+1 on the quarter

New · exited26 · 25

Reported value$508.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Essex Woodlands Management, Inc.unchanged · filed 4 Aug 2026	13,021,324$122.9M	00.0%
Juniper Investment Company, LLCunchanged · filed 14 Aug 2026	6,939,357$65.5M	00.0%
Nantahala Capital Management, LLCreduced · filed 14 Aug 2026	6,000,279$56.6M	-122,124−2.0%
BlackRock, Inc.added · filed 7 Aug 2026	3,435,914$32.4M	+302,373+9.6%
ROYCE & ASSOCIATES LPadded · filed 14 Aug 2026	1,833,212$17.3M	+291,930+18.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	1,751,678$16.5M	+36,971+2.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	1,365,716$12.9M	+197,469+16.9%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 2026	1,353,415$12.8M	+733,612+118.4%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026	1,128,465$10.7M	+255,327+29.2%
STATE STREET CORPadded · filed 7 Aug 2026	1,104,878$10.4M	+116,511+11.8%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Guido J. Neels Director · last 3 Jun 20260 · 0

Guy P. Nohra Director · last 3 Jun 20260 · 1

John A. Bartholdson Director, 10% owner · last 3 Jun 202611 · 0

Martin P. Sutter Director, 10% owner · last 3 Jun 20260 · 0

Mary Kay Ladone Director · last 3 Jun 20260 · 0

Michelle McMurry-Heath Director · last 3 Jun 20260 · 2

Pat Beyer Director · last 3 Jun 20260 · 0

Philip G. Cowdy Director · last 3 Jun 20260 · 0

Susan M. Stalnecker Director · last 3 Jun 20260 · 0

William A. Hawkins Director · last 3 Jun 20262 · 0

Anthony D'Adamio SVP & General Counsel · last 10 Apr 20261 · 11

CHURCH KATRINA J SVP & Chief Compliance Officer · last 10 Apr 20261 · 17

Same industry

RCEL Avita MedicalLeading+127%

HTFL HeartflowLeading+59%

PLSE Pulse BiosciencesLeading+51%

ATRC AtriCureLeading+51%

HAE HaemoneticsLeading+44%

INFU InfuSystems HoldingsLeading+32%

OBIO Orchestra BioMed HoldingsLeading+27%

SMTI Sanara MedTechLeading+23%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202568.3%

Operating profit marginFY 2025 · to 31 Dec 20259.5%

Free cash flow marginFY 2025 · to 31 Dec 202512.7%

Return on capital employedFY 2025 · to 31 Dec 202510.3%

Cash conversionFY 2025 · to 31 Dec 2025328%

Debt to equityFY 2025 · to 31 Dec 20251.60×

Research spendFY 2025 · to 31 Dec 20252.1%

Cash and equivalentsFY 2025 · to 31 Dec 2025$51.2M

Free cash flowFY 2025 · to 31 Dec 2025$72.1M

Analyst forecasts

No analyst forecasts yet.